Microbial Preparations (Probiotics) for the Prevention of Clostridium difficile Infection in Adults and Children: An Individual Patient Data Meta-analysis of 6,851 Participants

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To determine whether probiotic prophylaxes reduce the odds of Clostridium difficile infection (CDI) in adults and children. DESIGN: Individual participant data (IPD) meta-analysis of randomized controlled trials (RCTs), adjusting for risk factors. METHODS: We searched 6 databases and 11 grey literature sources from inception to April 2016. We identified 32 RCTs (n=8,713); among them, 18 RCTs provided IPD (n=6,851 participants) comparing probiotic prophylaxis to placebo or no treatment (standard care). One reviewer prepared the IPD, and 2 reviewers extracted data, rated study quality, and graded evidence quality. RESULTS: Probiotics reduced CDI odds in the unadjusted model (n=6,645; odds ratio [OR] 0.37; 95% confidence interval [CI], 0.25–0.55) and the adjusted model (n=5,074; OR, 0.35; 95% CI, 0.23–0.55). Using 2 or more antibiotics increased the odds of CDI (OR, 2.20; 95% CI, 1.11–4.37), whereas age, sex, hospitalization status, and high-risk antibiotic exposure did not. Adjusted subgroup analyses suggested that, compared to no probiotics, multispecies probiotics were more beneficial than single-species probiotics, as was using probiotics in clinical settings where the CDI risk is ≥5%. Of 18 studies, 14 reported adverse events. In 11 of these 14 studies, the adverse events were retained in the adjusted model. Odds for serious adverse events were similar for both groups in the unadjusted analyses (n=4,990; OR, 1.06; 95% CI, 0.89–1.26) and adjusted analyses (n=4,718; OR, 1.06; 95% CI, 0.89–1.28). Missing outcome data for CDI ranged from 0% to 25.8%. Our analyses were robust to a sensitivity analysis for missingness. CONCLUSIONS: Moderate quality (ie, certainty) evidence suggests that probiotic prophylaxis may be a useful and safe CDI prevention strategy, particularly among participants taking 2 or more antibiotics and in hospital settings where the risk of CDI is ≥5%. TRIAL REGISTRATION: PROSPERO 2015 identifier: CRD42015015701 Infect Control Hosp Epidemiol 2018;1–11

Details

Authors
  • Bradley C. Johnston
  • Lyubov Lytvyn
  • Calvin Ka Fung Lo
  • Stephen J. Allen
  • Duolao Wang
  • Hania Szajewska
  • Mark Miller
  • Stephan Ehrhardt
  • John Sampalis
  • Deniz G. Duman
  • Pietro Pozzoni
  • Agostino Colli
  • Elisabet Lönnermark
  • Christian P. Selinger
  • Samford Wong
  • Susan Plummer
  • Mary Hickson
  • Ruzha Pancheva
  • Sandra Hirsch
  • Joshua Z. Goldenberg
  • Li Wang
  • Lawrence Mbuagbauw
  • Gary Foster
  • Anna Maw
  • Behnam Sadeghirad
  • Lehana Thabane
  • Dominik Mertz
External organisations
  • Dalhousie University
  • McMaster University
  • Liverpool School of Tropical Medicine
  • Medical University of Warsaw
  • McGill University
  • Johns Hopkins Bloomberg School of Public Health
  • Marmara University
  • University of Gothenburg
  • St James's University Hospital
  • Stoke Mandeville Hospital
  • Plymouth University
  • University of Chile
  • Skåne University Hospital
  • Alessandro Manzoni Hospital
  • Cultech Ltd
  • Medical University of Varna
  • Bastyr University
  • St Joseph’s Healthcare Hamilton
  • University of Colorado-Denver
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Public Health, Global Health, Social Medicine and Epidemiology
Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalInfection Control and Hospital Epidemiology
Publication statusE-pub ahead of print - 2018 Apr 26
Publication categoryResearch
Peer-reviewedYes
Externally publishedYes